INT10799

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.78
First Reported 1981
Last Reported 2010
Negated 0
Speculated 4
Reported most in Abstract
Documents 63
Total Number 67
Disease Relevance 18.67
Pain Relevance 27.28

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

extracellular space (ENG) cell motility (ENG) cell adhesion (ENG)
nucleolus (ENG) nucleus (ENG) cytoplasm (ENG)
Anatomy Link Frequency
plasma 11
pituitary 7
hypothalamus 4
arcuate nucleus 2
serotonin neurons 2
ENG (Homo sapiens)
Pain Link Frequency Relevance Heat
Opioid 740 100.00 Very High Very High Very High
Endogenous opioid 208 100.00 Very High Very High Very High
Enkephalin 119 100.00 Very High Very High Very High
noradrenaline 50 100.00 Very High Very High Very High
gABA 27 100.00 Very High Very High Very High
Dopamine 6 100.00 Very High Very High Very High
Neuropeptide 3 100.00 Very High Very High Very High
Dynorphin 44 99.88 Very High Very High Very High
Analgesic 100 99.82 Very High Very High Very High
agonist 115 99.72 Very High Very High Very High
Disease Link Frequency Relevance Heat
Stress 210 100.00 Very High Very High Very High
Chronic Renal Failure 19 100.00 Very High Very High Very High
Pain 254 99.10 Very High Very High Very High
Endometriosis 13 98.96 Very High Very High Very High
Aids-related Complex 9 98.94 Very High Very High Very High
Arthritis 10 98.52 Very High Very High Very High
Cv General 3 Under Development 16 98.28 Very High Very High Very High
Peripheral Arterial Disease 63 98.10 Very High Very High Very High
INFLAMMATION 381 97.80 Very High Very High Very High
Cold Sores 25 97.76 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
These results indicate that: 1. secretion of beta-END-LI varies during different phases of the estrous cycle, 2. acute stress is a potent activator for beta-END-LI secretion, 3. no apparent increase of beta-END-LI in the blood plasma of ewes subjected to prolonged stress concomitant with accumulation of this material in pituitary (Polkowska and Przekop, 1988) supports the idea, that prolonged stress augments the synthesis of beta-END-LI but not its release.
Localization (secretion) of END in plasma associated with stress
1) Confidence 0.78 Published 1990 Journal Exp. Clin. Endocrinol. Section Abstract Doc Link 2245820 Disease Relevance 0.49 Pain Relevance 0
These results indicate that: 1. secretion of beta-END-LI varies during different phases of the estrous cycle, 2. acute stress is a potent activator for beta-END-LI secretion, 3. no apparent increase of beta-END-LI in the blood plasma of ewes subjected to prolonged stress concomitant with accumulation of this material in pituitary (Polkowska and Przekop, 1988) supports the idea, that prolonged stress augments the synthesis of beta-END-LI but not its release.
Localization (release) of END in plasma associated with stress
2) Confidence 0.68 Published 1990 Journal Exp. Clin. Endocrinol. Section Abstract Doc Link 2245820 Disease Relevance 0.43 Pain Relevance 0
These results do not support the hypothesis of a stimulatory effect for EPI on i beta END release and, instead, suggest that an inhibitory relationship may exist in humans experiencing stress.
Localization (release) of END in EPI associated with stress
3) Confidence 0.62 Published 1989 Journal J. Clin. Endocrinol. Metab. Section Abstract Doc Link 2527244 Disease Relevance 0.31 Pain Relevance 0.06
The present study evaluated the hypothesis that increased plasma levels of epinephrine (EPI) stimulate immunoreactive beta-endorphin (i beta END) secretion in humans experiencing a mild stress.
Localization (secretion) of END in plasma associated with stress
4) Confidence 0.62 Published 1989 Journal J. Clin. Endocrinol. Metab. Section Abstract Doc Link 2527244 Disease Relevance 0.24 Pain Relevance 0.09
The aim of the present study was to evaluate the expression of the neo-angiogenic marker endoglin and its localization in tissues of normal and endometriotic patients as well as to compare it with one new angiogenic marker candidate - S100A13.
Localization (localization) of endoglin associated with endometriosis
5) Confidence 0.61 Published 2005 Journal Reprod Biol Section Abstract Doc Link 15821778 Disease Relevance 0.35 Pain Relevance 0.13
Confocal immunofluorescence microscopy revealed that the opioid precursor POMC colocalizes with its active peptide END, key processing enzymes and MOR in alveolar macrophages, submucosal glands, cancerous cells, and pulmonary neuroendocrine cells within the bronchial epithelium.
Localization (colocalizes) of END in neuroendocrine cells associated with opioid receptor and opioid
6) Confidence 0.58 Published 2010 Journal Pharmacol Rep Section Abstract Doc Link 20360624 Disease Relevance 0.32 Pain Relevance 0.95
ESRD End stage renal disease
Localization (disease) of End associated with chronic renal failure
7) Confidence 0.48 Published 2007 Journal Cost Eff Resour Alloc Section Body Doc Link PMC2217271 Disease Relevance 1.32 Pain Relevance 0.09
Immunolocalization of MMP9, MMP2, type IV Collagen, macrophages and CD105 were performed using streptavidin-biotin peroxidase complex method (SP).
Localization (Immunolocalization) of CD105 in macrophages
8) Confidence 0.30 Published 2010 Journal J Transl Med Section Body Doc Link PMC2965128 Disease Relevance 0.53 Pain Relevance 0.09
We assumed that the rise in end-tidal CO2 had occurred due to secretions in the airway.
Localization (secretions) of end-tidal
9) Confidence 0.25 Published 2008 Journal J Anesth Section Abstract Doc Link 19011791 Disease Relevance 0.68 Pain Relevance 0.17
In the present study the effects of intravenously administered corticotropin-releasing hormone (CRH) on the release of proopiomelanocortin (POMC) derivatives such as adrenocorticotropic hormone (ACTH), beta-lipotropin (beta-LPH) and beta-endorphin (beta-END) as well as direct effects of CRH on pain sensitivity were examined.
Spec (examined) Localization (release) of beta-END associated with pain
10) Confidence 0.24 Published 2005 Journal Neuroendocrinology Section Abstract Doc Link 16534240 Disease Relevance 0.39 Pain Relevance 0.53
We found the significant increase in MTT reduction by neutrophils in the presence of M-ENK and beta-END both before and after the culture.
Localization (presence) of beta-END in neutrophils
11) Confidence 0.22 Published 2002 Journal Mediators Inflamm Section Abstract Doc Link PMC1781664 Disease Relevance 0.57 Pain Relevance 0.41
IPFP cells at passage 2 expanded with and without FGF-2 stained strongly for CD13, CD44, CD90, and CD105 (markers for mesenchymal stem cells) and for CD29 (?
Localization (markers) of CD105 in stem cells associated with peripheral arterial disease
12) Confidence 0.21 Published 2008 Journal Arthritis Res Ther Section Body Doc Link PMC2575620 Disease Relevance 0.47 Pain Relevance 0
To evaluate analgesic effects of CRH via release of POMC derivatives, we determined plasma concentrations of beta-END-immunoreactive material (IRM), authentic beta-END (beta-END(1-31)) and beta-LPH IRM, in parallel with heat and pressure pain tolerance thresholds before and 15 and 30 min after treatment with CRH (or placebo), and 5 min after naloxone (or placebo) administration which was administered 40 min after CRH (or placebo) injection.
Localization (release) of beta-END in plasma associated with pain, analgesic, narcan and tolerance
13) Confidence 0.21 Published 2005 Journal Neuroendocrinology Section Abstract Doc Link 16534240 Disease Relevance 0.54 Pain Relevance 0.83
Also, these effects could not be enhanced by increasing END release through stress or by modifying POMC-MIDGE-NLS to code for multiple copies of END (Fig. 5, Fig. 6).
Localization (release) of END associated with stress
14) Confidence 0.12 Published 2009 Journal Mol Pain Section Body Doc Link PMC2797781 Disease Relevance 0.55 Pain Relevance 0.46
Here, we examined whether swim stress can stimulate the secretion of END, possibly overcoming the variability in its leukocytic content, and increase its anti-hyperalgesic actions.
Localization (secretion) of END associated with stress and hyperalgesia
15) Confidence 0.12 Published 2009 Journal Mol Pain Section Body Doc Link PMC2797781 Disease Relevance 0.94 Pain Relevance 0.31
Our major objective was to enhance the production and release of END in inflamed tissue using POMC-MIDGE-NLS to provide continuous relief of inflammatory pain.


Localization (release) of END associated with ipn
16) Confidence 0.11 Published 2009 Journal Mol Pain Section Body Doc Link PMC2797781 Disease Relevance 0.69 Pain Relevance 0.96
Recent in vitro studies have shown that the release of hypothalamic beta-endorphin (beta-END), like that of adenohypophysial origin, is enhanced by both corticotropin-releasing hormone (CRH) and arginine vasopressin (AVP).
Localization (release) of beta-END
17) Confidence 0.10 Published 1991 Journal Neuroendocrinology Section Abstract Doc Link 1766548 Disease Relevance 0 Pain Relevance 0
It was found in our earlier experiments that infusion of beta-endorphin (beta-End) into the 3rd brain ventricle in sheep elicited a differential effect on the secretion of cortisol under physiological and stress conditions.
Localization (secretion) of beta-End in brain ventricle associated with stress
18) Confidence 0.10 Published 1993 Journal Neuroendocrinology Section Abstract Doc Link 8479608 Disease Relevance 0.30 Pain Relevance 0
Measurements of systolic PAP, TAPSE, RVFAC, end-diastolic right atrial diameter, end-diastolic right/left ventricular ratio and biochemical parameters of right ventricular overload are presented in Table 2.
Localization (presented) of end
19) Confidence 0.10 Published 2010 Journal BMC Pulm Med Section Body Doc Link PMC2859373 Disease Relevance 0.17 Pain Relevance 0.06
However, whereas AVP merely synergizes with CRH in the pituitary, it seems to be essential for the release of hypothalamic beta-END by CRH.
Localization (release) of beta-END in pituitary
20) Confidence 0.09 Published 1991 Journal Neuroendocrinology Section Abstract Doc Link 1766548 Disease Relevance 0 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox